Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CSPHF - Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal

CSPHF - Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal

CStone Pharmaceuticals - Ordinary Shares
  • CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement.
  • CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal.
  • Shanghai's Zai Lab has started a China Phase Ib trial of retifanlimab, an anti-PD1 antibody.

For further details see:

Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal
Stock Information
Company Name: CStone Pharmaceuticals - Ordinary Shares
Stock Symbol: CSPHF
Market: OTC
Menu
CSPHF CSPHF Quote CSPHF Short CSPHF News CSPHF Articles CSPHF Message Board
Get CSPHF Alerts

News, Short Squeeze, Breakout and More Instantly...